Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $32.58

Denali Therapeutics Inc. (NASDAQ:DNLI) has received an average recommendation of “Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $32.5833.

Several research analysts have issued reports on DNLI shares. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Denali Therapeutics in a report on Friday, December 5th. Wedbush cut their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Stifel Nicolaus set a $37.00 price target on shares of Denali Therapeutics in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new position in shares of Denali Therapeutics in the second quarter valued at approximately $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics in the 3rd quarter valued at $29,000. State of Wyoming bought a new position in Denali Therapeutics during the 2nd quarter valued at $29,000. Quarry LP purchased a new position in Denali Therapeutics during the 3rd quarter worth $64,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Trading Down 0.7%

DNLI opened at $16.87 on Friday. The company has a fifty day moving average price of $17.30 and a two-hundred day moving average price of $15.51. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $24.34. The company has a market cap of $2.47 billion, a P/E ratio of -5.80 and a beta of 1.11. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.63) EPS. Analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.